![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
EYEN = Market Cap $51 M --Cash $18 M-- 1 Big drug close to NDA submission another 2 Drug in Phase 3 with readouts by next year 1 Big Drug is NDA ready -- Another 2 Big Drugs in Phase 3 with readouts expected in 2H 2020 -- MASSIVE Insider buying --Low float Stock -- CEO/CMO Ianchulev is the great scientist who lead the development of themega Blockbuster Lucentis =BRUTALLY UNDERPRICED STOCK WITH MASSIVE UPSIDE POTENTIAL !!! GL Eyenovia (EYEN) Market Cap $51 M Cash $18.4 M Price $3 Shares Out 17.1 M Presentation ir.eyenoviabio.com Insider buying openinsider.com MicroStat (Indication: Mydriasis) File NDA $300 M+ Market Opportunity MicroLine (indication:Presbyopia) Initiate and Complete Phase III VISION Study $2 B+ Market Opportunity MicroPine (Indication: Progressive Myopia) Complete Phase III CHAPERONE Enrollment $ 5B+ Market Opportunity ![]()
| ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |